In this article, we will list the 5 Best Medical AI Stocks to Buy Now. Please visit 10 Best Medical AI Stocks to Buy Now if you would like to see the extended list and the methodology behind it.
5. Teladoc Health Inc (NYSE:TDOC)
Number of Hedge Fund Holders: 36
Upside Potential: 24.57%
Teladoc Health Inc (NYSE:TDOC) is among the best medical AI stocks to buy now. On March 31, activist investor Pineal Capital Management urged Teladoc to launch a share repurchase program. Pineal Capital is pushing for at least $200 million in share buybacks. Additionally, the activist investor has called on the Teladoc management to consider separating the company’s two main business segments. Teladoc’s Integrated Care segment serves employers and health plans, while its BetterHelp segment offers a mental health platform.
Notably, the Pineal Capital Management push comes after Teladoc outlined its plans for 2026. The company aims to build on the progress it made last year on strengthening the product portfolio and advancing innovation. Addressing investors in the Q4 2025 report on February 25, Teladoc CEO Chuck Divita said this year they’re focused on strengthening their ability to meet the evolving needs of their clients.
Teladoc Health Inc (NYSE:TDOC) is integrating AI to enhance its solutions for hospitals and health systems. It has built an AI-powered workplace safety feature for healthcare settings. The company says that workplace violence is a growing challenge for hospitals, costing them more than $18 billion annually.
Teladoc also offers an AI-driven solution to help hospitals improve patient safety, such as preventing patient falls. The company says patient falls result in around $50 billion in extra medical costs for hospitals each year. Microsoft is one of Teladoc’s AI partners.
Teladoc anticipates 2026 revenue in the band of $2.47 billion to $2.59 billion. That compares to the 2025 revenue of $2.53 billion. The company exited 2025 with $781.1 million in cash and cash equivalents.
Teladoc Health Inc (NYSE:TDOC), headquartered in New York City, provides around-the-clock virtual medical care. It connects patients to doctors through phone and video. Through the Teladoc platform, patients can get on-demand diagnosis, chronic condition management, mental health services, and treatment for illnesses like the flu and allergies.
4. Tempus AI Inc (NASDAQ:TEM)
Number of Hedge Fund Holders: 41
Upside Potential: 46.18%
Tempus AI Inc (NASDAQ:TEM) is among the best medical AI stocks to buy now. Tempus has partnered with SoftBank, Gilead, and Merck on AI-driven drug development programs. Analysts are growing more confident in Tempus amid its expanding partnerships. On April 13, TD Cowen upgraded Tempus AI Inc (NASDAQ:TEM) to a Buy rating from Hold, though it lowered the price target to $65 from $70. TD Cowen analyst Dan Brennan pointed to the company’s strong fundamentals for the upgrade, though Brennan noted the stock has eased around 50% over the past six months.
According to TD Cowen, Tempus’ Insights business is well-positioned for accelerated growth and forecast beat in 2026. The firm also expects continued growth in Tempus’ Genomics business. Tempus’ revenue increased 83.4% to $1.3 billion in 2025. The company is anticipating 2026 revenue to be $1.59 billion, implying a growth of 25%.
The Tempus-SoftBank pact, unveiled in June 2024, is structured as a joint venture and involves Tempus bringing its AI-driven treatment and clinical trial recommendations to the Japanese market.
Japan’s AI in healthcare market size is forecast to reach $2.29 billion by 2034 from $545.3 million in 2025, according to IMARC Group estimates. Factors like the increasing need for personalized medication, growing interest in remote patient monitoring, and the growing need to accurately forecast patient results are driving the market growth.
Tempus AI Inc (NASDAQ:TEM), based in Chicago, Illinois, offers precision medicine services. It makes use of data and artificial intelligence for this work. Although the company is primarily focused on cancer treatment, it’s expanding into areas like cardiology and infectious diseases. Tempus AI was founded in 2015 by billionaire Eric Lefkofsky.
3. iRhythm Holdings, Inc (NASDAQ:IRTC)
Number of Hedge Fund Holders: 44
Upside Potential: 69.53%
iRhythm Holdings, Inc (NASDAQ:IRTC) is among the best medical AI stocks to buy now. At the American College of Cardiology 2026 Annual Scientific Sessions on March 30, iRhythm shared analysis results that cast its cardiac monitoring service in a favorable light. The studies analyzed data from thousands of patients using iRhythm’s Zio cardiac monitoring device. The company provides cardiac monitoring devices and software that use artificial intelligence.
In one study, the analysis found that there were clinically actionable arrhythmias in 48% of patients with chronic kidney disease and 47% of patients with both chronic kidney disease and diabetes. That compared with 39% of patients with diabetes only and 35% of patients with none of these conditions. This study reviewed data from 657,147 people who received 14 days of continuous monitoring.
In a second study, the analysis showed that patients with severe obesity were 2.8 times more likely to be found with atrial fibrillation detection compared to normal or underweight patients.
On the day iRhythm shared these study results, it announced the launch of an education platform targeting healthcare professionals in cardiac monitoring. The company calls it the iRhythm Academy. iRhythm is trying to educate doctors about its cardiac monitoring products at a time when it’s targeting an expanding market. The global market for smart wearable ECG monitors, such as iRhythm’s Zio, is on course to grow from $1.98 billion in 2024 to $3.54 billion by 2030, according to Grand View Research.
iRhythm’s revenue rose 26.2% to $747.1 million in 2025. This growth was due to increased demand for Zio services. The Q4 2025 revenue of $208.9 million increased 27.1% YoY and surpassed the consensus projection of $201.8 million.
iRhythm Holdings, Inc (NASDAQ:IRTC) is a digital healthcare company based in California. It offers cardiac monitoring services to help detect and prevent disease. Its portfolio includes monitoring devices and accompanying software solutions. iRhythm’s Zio cardiac monitor device is a lightweight adhesive patch worn on the chest.
2. Veeva Systems Inc (NYSE:VEEV)
Number of Hedge Fund Holders: 75
Upside Potential: 57.51%
Veeva Systems Inc (NYSE:VEEV) is among the best medical AI stocks to buy now. Wall Street is taking note of Veeva’s AI efforts, and many believe the company is moving in the right direction. On April 1, Stifel reaffirmed its Buy rating and $245 price target on Veeva Systems stock, citing the company’s AI opportunities.
Stifel renewed its bullish stance on Veeva stock after finding out that Veeva is a preferred vendor in the life sciences CRM space. The firm came to this conclusion following discussions with industry participants.
The findings showed that large pharmaceutical companies want to work with technology partners to weave AI capabilities into their platforms rather than doing it on their own. Stifel noted from the calls that even an existing Salesforce CRM customer was open to switching to a different provider.
It has embedded AI agents and AI shortcuts into its platform to help companies automate tasks and improve workforce productivity. To further build its AI capabilities, Veeva Systems announced on March 10 that it has acquired Ostro.
Ostro provides an AI-powered patient-doctor chat platform that delivers quick and 100% compliant responses. Veeva bought Ostro for around $100 million in cash and equity. Ostro will initially operate as a standalone unit but over time it will be integrated into Veeva to ensure a seamless workflow.
Veeva posted Q4 2025 financial results that exceeded expectations. Revenue rose 16% YoY to $836 million and surpassed the consensus estimate of $810.67 million. EPS of $2.06 topped the forecast of $1.93.
Veeva Systems Inc (NYSE:VEEV), founded in 2007 and based in California, provides cloud software, data, and analytics to the life sciences industry. Its solutions help drug and medical device companies to develop, test, and market their products faster and more efficiently. Veeva Systems customers include Bayer, Eli Lilly, Gilead Sciences, and Merck.
1. Boston Scientific Corp (NYSE:BSX)
Number of Hedge Fund Holders: 108
Upside Potential: 54.91%
Boston Scientific Corp (NYSE:BSX) is among the best medical AI stocks to buy now. Piper Sandler reaffirmed its Overweight rating on Boston Scientific Corp (NYSE:BSX) stock on April 6. This followed the release of the Champion-AF study results of Boston Scientific’s Watchman heart implant. The firm renewed its bullish stance on Boston Scientific stock after hosting a discussion with a doctor who performs high-volume heart implants. That discussion centered on cardiac device usage.
Piper Sandler expects Watchman sales to increase 20% annually for the next several years. It added that this should contribute around 200 basis points to Boston Scientific’s topline growth.
In the Champion-AF study, Boston Scientific’s Watchman heart implant met all primary and secondary endpoints regarding safety and efficiency. That study evaluated the Watchman device as a first-line treatment option for stroke risk reduction. There are more than 59 million people globally with a heart rhythm disorder who could benefit from the Watchman implant.
In 2025, Boston Scientific’s net sales grew 19.9% to $20 billion, and adjusted EPS came to $3.06, compared to $2.51 in the prior year. Boston Scientific CEO Mike Mahoney said 2025 was another exceptional year for the company, noting that they exceeded their goals. The company expects the growth to continue, forecasting topline growth of at least 10.5% in 2026.
Boston Scientific Corp (NYSE:BSX) is an American multinational biotechnology and biomedical engineering company. It makes medical devices used to address cardiovascular, respiratory, and neurological conditions. Boston Scientific was founded in 1979 and is based in Massachusetts.
While we acknowledge the potential of BSX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BSX and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: David Abrams’ Hedge Fund Is Betting On These 8 Stocks and 10 Best Energy Storage Stocks to Buy According to Hedge Funds.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.
